{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:03:36Z","timestamp":1784952216021,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1053\/j.ajkd.2022.04.006","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T22:37:31Z","timestamp":1653604651000},"page":"730-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Initiation Dose of Allopurinol and the Risk of Severe Cutaneous Reactions in Older Adults With CKD: A\u00a0Population-Based Cohort Study"],"prefix":"10.1053","volume":"80","author":[{"given":"Lavanya","family":"Bathini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Sontrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie N.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flory T.","family":"Muanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2022.04.006_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-020-00967-8","article-title":"Something old, something new: the ACR gout treatment guideline and its evolution from 2012 to 2020","volume":"23","author":"Cohen","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1053\/j.ajkd.2022.04.006_bib2","series-title":"Allopurinol","author":"Qurie","year":"2021"},{"issue":"4","key":"10.1053\/j.ajkd.2022.04.006_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating\u00a0the cause and minimizing the risk","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2022.04.006_bib7","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/rheumatology\/kex422","article-title":"How to prevent allopurinol hypersensitivity reactions?","volume":"57","author":"Stamp","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1053\/j.ajkd.2022.04.006_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2022.04.006_bib9","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"ACR gout guideline 2020","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"39","key":"10.1053\/j.ajkd.2022.04.006_bib10","doi-asserted-by":"crossref","first-page":"E1070","DOI":"10.1503\/cmaj.190339","article-title":"Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study","volume":"191","author":"Yokose","year":"2019","journal-title":"CMAJ"},{"issue":"8","key":"10.1053\/j.ajkd.2022.04.006_bib11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2017-212905","article-title":"Racial\/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study","volume":"77","author":"Keller","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2022.04.006_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101501","article-title":"Allopurinol hypersensitivity: pathogenesis and prevention","volume":"34","author":"Stamp","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"10.1053\/j.ajkd.2022.04.006_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","article-title":"Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level","volume":"90","author":"Stamp","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1053\/j.ajkd.2022.04.006_bib15","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1053\/j.ajkd.2022.04.006_bib16","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1053\/j.ajkd.2022.04.006_bib17","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions a nationwide population-based study in Taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1053\/j.ajkd.2022.04.006_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The Reporting of studies conducted using observational routinely-collected health data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"issue":"2","key":"10.1053\/j.ajkd.2022.04.006_bib21","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"issue":"5","key":"10.1053\/j.ajkd.2022.04.006_bib23","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1681\/ASN.2004080697","article-title":"Identifying individuals with a reduced GFR using ambulatory laboratory database surveillance","volume":"16","author":"Garg","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2022.04.006_bib24","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/01.EDE.0000081989.82616.7d","article-title":"Marginal structural models as a tool for standardization","volume":"14","author":"Sato","year":"2003","journal-title":"Epidemiology"},{"issue":"5","key":"10.1053\/j.ajkd.2022.04.006_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"10.1053\/j.ajkd.2022.04.006_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"28","key":"10.1053\/j.ajkd.2022.04.006_bib27","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"7","key":"10.1053\/j.ajkd.2022.04.006_bib28","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A\u00a0modified poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1053\/j.ajkd.2022.04.006_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 Updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2022.04.006_bib30","first-page":"461","article-title":"Allopurinol initiation and all-cause mortality among patients with gout and concurrent chronic kidney disease: a population-based cohort study","volume":"175","author":"Wei","year":"2022","journal-title":"Ann\u00a0Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2022.04.006_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2016.03.014","article-title":"Racial disparities in the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the US HHS Public Access","volume":"46","author":"Lu","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1053\/j.ajkd.2022.04.006_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jaip.2018.07.022","article-title":"Identification of inpatient allergic drug reactions using ICD-9-CM codes","volume":"7","author":"Saff","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1053\/j.ajkd.2022.04.006_bib33","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"issue":"1)(suppl 2","key":"10.1053\/j.ajkd.2022.04.006_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0272-6386(03)00415-3","article-title":"Adapting the Charlson comorbidity index for use in patients with ESRD","volume":"42","author":"Hemmelgarn","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2022.04.006_bib35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622007041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622007041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:43:26Z","timestamp":1759463006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638622007041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0272638622007041"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.04.006","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiation Dose of Allopurinol and the Risk of Severe Cutaneous Reactions in Older Adults With CKD: A\u00a0Population-Based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}